Highlights

• “I think the fact that they are in a single tablet is not the important thing, it is actually the drugs which are much more important, and then if they were to be available in a single tablet, then you would give them as a single tablet.”
  
• “Well, it is a very good regimen with very good results. I think, clearly, bictegravir and dolutegravir are your leading integrase inhibitors. I think clearly dolutegravir, because it has been around longer, has got issues which have developed. I think clearly that will happen with bictegravir as well, though it is nice and shiny and clean at the present time.”
  
• “It [Delstrigo] is a very interesting drug, but they have to make a decision whether they want to be the best non-nucleoside, in which case their market is limited, or a real player in the kind of naïve initial therapy switch market, but that is going to be driven for them purely by its price.